SCYNEXIS (SCYX) Q3 2024 earnings summary

Executive summary

• SCYNEXIS focuses on developing novel antifungal agents, with ibrexafungerp as its lead product and SCY-247 in preclinical development. FDA approvals for BREXAFEMME cover VVC and RVVC, but a product recall and clinical hold were initiated due to potential beta-lactam cross-contamination. The company is working to resolve the issue and anticipates restarting the MARIO study in Q1 2025.

• A $10 million milestone was received from GSK in Q3 2024, bringing total upfront and development milestone receipts to $125 million under the GSK License Agreement.

Financial highlights

• For the three months ended September 30, 2024, total revenue was $0.7 million, down from $2.4 million in the same quarter last year, driven by lower license agreement revenue.

• Net loss for the quarter was $2.8 million, compared to a net loss of $1.8 million in Q3 2023.

• For the nine months ended September 30, 2024, total revenue was $2.8 million, down from $134.3 million in the prior year period, reflecting the absence of the large upfront GSK license payment recognized in 2023.

• Net loss for the nine-month period was $16.9 million, compared to net income of $86.6 million in the prior year period.

• Cash, cash equivalents, and investments totaled $84.9 million as of September 30, 2024.

Outlook and guidance

• Management believes current capital resources are sufficient to fund operations for at least 12 months from the reporting date.

• The company expects to incur significant R&D and SG&A expenses and may seek additional capital through equity, debt, or partnerships.

• Anticipates restarting the MARIO study after FDA lifts the clinical hold, targeted for Q1 2025.